Enliven Therapeutics (NASDAQ:ELVN) Price Target Raised to $82.00

Enliven Therapeutics (NASDAQ:ELVN) had its price objective increased by research analysts at Stifel Nicolaus from $80.00 to $82.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Stifel Nicolaus’ price objective indicates a potential upside of 35.83% from the company’s previous close.

A number of other equities research analysts also recently weighed in on ELVN. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Friday, July 17th. HC Wainwright increased their target price on shares of Enliven Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a research note on Thursday, July 9th. JonesTrading boosted their target price on shares of Enliven Therapeutics from $45.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Wall Street Zen upgraded Enliven Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, May 11th. Finally, Mizuho upped their target price on shares of Enliven Therapeutics from $45.00 to $62.00 and gave the company an “outperform” rating in a research note on Tuesday, June 2nd. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $72.67.

Enliven Therapeutics Stock Up 1.1%

Shares of ELVN stock traded up $0.67 during trading hours on Thursday, hitting $60.37. 145,349 shares of the company were exchanged, compared to its average volume of 1,279,107. The firm has a fifty day moving average of $47.81 and a 200 day moving average of $39.29. The firm has a market cap of $3.68 billion, a PE ratio of -36.17 and a beta of 0.27. Enliven Therapeutics has a 1 year low of $14.78 and a 1 year high of $62.32.

Enliven Therapeutics (NASDAQ:ELVN) last posted its earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.10). Analysts expect that Enliven Therapeutics will post -1.57 earnings per share for the current year.

Insider Buying and Selling

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 6,018 shares of the firm’s stock in a transaction on Friday, July 17th. The stock was sold at an average price of $52.64, for a total transaction of $316,787.52. Following the transaction, the chief financial officer directly owned 46,054 shares in the company, valued at approximately $2,424,282.56. This trade represents a 11.56% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Anne Kunkel sold 10,000 shares of the stock in a transaction on Monday, July 6th. The stock was sold at an average price of $50.49, for a total value of $504,900.00. Following the completion of the sale, the director owned 41,884 shares in the company, valued at $2,114,723.16. This trade represents a 19.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 32,036 shares of company stock worth $1,430,676 over the last ninety days. 3.00% of the stock is owned by insiders.

Hedge Funds Weigh In On Enliven Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Enliven Therapeutics by 8.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,729 shares of the company’s stock valued at $428,000 after buying an additional 1,693 shares during the period. Goldman Sachs Group Inc. increased its holdings in Enliven Therapeutics by 61.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 211,752 shares of the company’s stock valued at $4,167,000 after purchasing an additional 80,506 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Enliven Therapeutics in the first quarter valued at approximately $578,000. Legal & General Group Plc increased its position in shares of Enliven Therapeutics by 52.2% during the second quarter. Legal & General Group Plc now owns 32,225 shares of the company’s stock worth $646,000 after acquiring an additional 11,058 shares during the period. Finally, Quantbot Technologies LP increased its stake in shares of Enliven Therapeutics by 47.1% during the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after buying an additional 1,434 shares during the period. 95.08% of the stock is owned by institutional investors.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.